Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $20.86 million versus the consensus estimate of $16.38 million.

"We continue to demonstrate progress in all of the key value drivers for Rigel," said Raul Rodriguez, Rigel's president and CEO. "Our commercial business continues to expand with U.S. sales increasing 15% quarter over quarter. We are moving forward with regulatory and collaborative efforts in Europe, Japan, and Canada to potentially make fostamatinib available to ITP patients globally; our Phase 3 trial for fostamatinib in warm autoimmune hemolytic anemia is enrolling; and we have strengthened our pipeline with progress in our IRAK1/4 and RIP1 programs. All of these achievements create valuable opportunities for Rigel both in the near and long term."

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.